Quantcast
Last updated on April 16, 2014 at 14:14 EDT

Latest Radiopharmacology Stories

2012-06-11 21:24:03

Study finds that a combination of molecular imaging, radiography and dual imaging probes detects more cancerous bone lesions than other methods Research revealed at the Society of Nuclear Medicine's 2012 Annual Meeting describes new approaches to imaging for the detection of tumors in complex cases of bone cancer. Hybrid imaging technology combining computed tomography (CT) with molecular imaging agents targeting two different markers of disease came out on top of the list for the...

2012-06-05 06:29:06

LUBBOCK, Texas, June 5, 2012 /PRNewswire/ -- Positron Corporation a leading molecular imaging healthcare company, specializing in the field of nuclear cardiology announces completion of its first strontium validation effort. In May 2012, Manhattan Isotope Technology (MIT), a Positron subsidiary, successfully processed strontium. The internal analysis of the product demonstrates it meets the Sr-82 purity specifications required for the formulation of Sr-82/Rb-82 generators. MIT has now...

2012-05-27 22:20:14

MONTREAL, May 28, 2012 /PRNewswire/ - We are pleased to announce the appointment of Mr. Martyn Coombs as President, Jubilant DraxImage Inc. at Montreal, Canada with effect from May 23, 2012. Prior to joining Jubilant DraxImage, Mr. Coombs served as CEO of Asterand PLC from 2007 to 2011. During his term, he received an award from the Financial Times for the top performing stock on the London Stock Exchange, out of over 2,000 companies. Previously, he served in Japan for five...

2012-03-23 06:22:35

CROWN POINT, Ind., March 23, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging healthcare company, specializing in the field of nuclear cardiology announces the approval of their Nuclear Regulatory Commission (NRC) manufacturing and distribution license amendment for the Company's radiopharmaceutical manufacturing facility in Crown Point, Indiana. Positron received its pharmacy license from the Indiana Board of Pharmacy in December 2011, which...

2012-02-22 10:39:00

LUBBOCK, Texas, Feb. 22, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 15, 2012, MIT, in partnership with Los Alamos National Laboratory, was awarded the 2012 Federal Laboratory Consortium 'Excellence in Technology Transfer Award' for "Recycling of Strontium-82 for Use in Medical Diagnostic Imaging". The Award for Excellence in Technology Transfer is presented...

2012-02-21 09:10:00

LUBBOCK, Texas, Feb. 21, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 16, 2012, MIT, received its first shipment of strontium-82(Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France. This historic event marks the first shipment of Sr-82 to be received by a private, non-government, entity in the U.S. in support of Sr-82 production. The receipt of this...

2012-02-07 08:57:00

FISHERS, Ind., Feb. 7, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is pleased to announce the execution of a Memorandum of Understanding with the Institute of Nuclear Research (INR) of Troitsk, Russia. MIT and INR will collaborate on strontium-82(Sr-82) production beginning with a pharmaceutical ingredient validation exercise in 2012. A key goal of the collaboration is to increase the annual...

2012-01-30 05:00:00

Canadian centre of excellence partners with US-based Molecular Insight Pharmaceuticals to manufacture a new radiopharmaceutical for clinical trials that will evaluate the potential to deliver targeted radiotherapy directly to metastatic prostate cancer. HAMILTON, ON, and CAMBRIDGE, MA, Jan. 30, 2012 /PRNewswire/ - A new targeted radiopharmaceutical, designed to deliver a therapeutic dose of radiation directly to metastatic prostate cancer, will be manufactured in Hamilton, Ontario...

2012-01-27 12:46:00

FISHERS, Ind., Jan. 27, 2012 /PRNewswire/ -- Positron Corporation (OTCBB:POSC), a leading molecular imaging healthcare company, specializing in the field of nuclear cardiology, is pleased to announce that on January 23, 2012, its wholly owned subsidiary, Manhattan Isotope Technology (MIT), received approval of its radioactive materials license amendment. The Texas Department of State Health Services- Radiation Control Program granted the amendment approval. This specific...

2012-01-17 09:13:00

FISHERS, Ind., Jan. 17, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce the acquisition of Manhattan Isotope Technology, LLC (MIT). Positron has acquired all of the assets, business operations and retained all employees of MIT. In exchange, MIT shall receive cash advances, assumption of certain indebtedness and earn-out consideration of $3,500,000 based on 20 percent...